Your browser doesn't support javascript.
loading
Lymph node yield in the pathological staging of resected nonmetastatic colon cancer: The more the better?
Simões, Pedro; Fernandes, Gonçalo; Costeira, Beatriz; Machete, Madalena; Baptista, Carlota; N Silva, Diana; Leal-Costa, Luísa; Prazeres, Gil; Correia, Jorge; Albuquerque, Joana; Padrão, Teresa; Gomes, Catarina; Godinho, João; Faria, Ana; Casa-Nova, Mafalda; Lopes, Fábio; Teixeira, José A; F Pulido, Catarina; Oliveira, Helena; Mascarenhas-Lemos, Luís; Albergaria, Diogo; Maio, Rui; Passos-Coelho, José L.
Afiliación
  • Simões P; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: pedro.simoes@hbeatrizangelo.pt.
  • Fernandes G; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: goncalo.fernandes@hospitaldaluz.pt.
  • Costeira B; General Surgery, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: beatrizacosteira@gmail.com.
  • Machete M; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: maria.machete@hbeatrizangelo.pt.
  • Baptista C; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: carlota.vieira.baptista@hbeatrizangelo.pt.
  • N Silva D; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: diana.neto.silva@hbeatrizangelo.pt.
  • Leal-Costa L; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: maria.leal.costa@hbeatrizangelo.pt.
  • Prazeres G; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: gil.martins.prazeres@hospitaldaluz.pt.
  • Correia J; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: jorge.alves.correia@hospitaldaluz.pt.
  • Albuquerque J; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: joana.duarte.albuquerque@hospitaldaluz.pt.
  • Padrão T; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: ana.padrao@hospitaldaluz.pt.
  • Gomes C; Gastroenterology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: catarinagomes27@gmail.com.
  • Godinho J; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: joao.godinho@hbeatrizangelo.pt.
  • Faria A; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: ana.faria@hbeatrizangelo.pt.
  • Casa-Nova M; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: mafalda.peres@hbeatrizangelo.pt.
  • Lopes F; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: fabio.lopes@hbeatrizangelo.pt.
  • Teixeira JA; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: jose.teixeira@hbeatrizangelo.pt.
  • F Pulido C; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: catarina.pulido@hospitaldaluz.pt.
  • Oliveira H; Pathology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: mariahelenasousaoliveira@gmail.com.
  • Mascarenhas-Lemos L; Pathology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal; Pathology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: luisalbuquerquemascarenhas@gmail.com.
  • Albergaria D; General Surgery, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal. Electronic address: diogo.albergaria@hbeatrizangelo.pt.
  • Maio R; General Surgery, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal; General Surgery, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: rui.maio@hospitaldaluz.pt.
  • Passos-Coelho JL; Medical Oncology, Hospital Beatriz Ângelo, Av. Carlos Teixeira 3, 2674-514, Loures, Portugal; Medical Oncology, Hospital da Luz Lisboa, Av. Lusíada 100, 1500-650, Lisbon, Portugal. Electronic address: passoscoelho@sapo.pt.
Surg Oncol ; 43: 101806, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35841744
INTRODUCTION: Guidelines recommend regional lymphadenectomy with a lymph node yield (LNY) of at least 12 lymph nodes (LN) for adequate colon cancer (CC) staging. LNY ≥22LN may improve survival, especially in right-sided CC [Lee et al., Surg Oncol, 27(3), 2018]. This multicentric retrospective cohort study evaluated the impact of LNY and tumor laterality on CC staging and survival. MATERIALS AND METHODS: Patients with stage I-III CC that underwent surgery from 2012 to 2018 were grouped according to LNY: <22 and ≥ 22. Primary outcomes were LN positivity (N+ rate) and disease-free survival (DFS). Overall survival (OS) was the secondary outcome. Exploratory analyses were performed for laterality and stage. RESULTS: We included 795 patients (417 < 22LN, 378 ≥ 22LN); 53% had left-sided CC and 29%/37%/38% had stage I/II/III tumors. There was no association between LNY ≥22LN and N+ rate after adjustment for grade, T stage, lymphovascular invasion (LVI) and perineural invasion; a trend for a higher N+ rate in left-sided CC was identified (interaction p = 0.033). With a median follow-up of 63.6 months for DFS and 73.2 months for OS, 254 patients (31.9%) relapsed and 207 (26.0%) died. In multivariate analysis adjusted for age, ASA score, laparoscopic approach, T/N stage, mucinous histology, LVI and adjuvant chemotherapy, LNY ≥22LN was significantly associated with both DFS (HR 0.75, p = 0.031) and OS (HR 0.71, p = 0.025). Restricted cubic spline analysis showed a more significant benefit for right-sided CC. CONCLUSION: LNY ≥22LN was associated with longer DFS and OS in patients with operable CC, especially for right-sided CC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Colon / Ganglios Linfáticos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Colon / Ganglios Linfáticos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos